Orca Bio announced that new clinical data will be presented at the American Society of Hematology Annual Meeting from December 10-13.
- Oral presentation to highlight impressive results with Orca-T on relapse-free survival (RFS) at one year in the Phase 1b/2 clinical trials
- Oral presentation will detail first data readout of Orca-Q in haploidentical allogeneic transplant demonstrating favorable graft-versus-host disease and relapse-free survival (GRFS) at one year in patients with hematologic malignancies
- Poster presentation will demonstrate the mechanism of action of Orca-T for blood and immune reconstitution
- Poster presentation to show the health economic benefit to the US healthcare system of doubling the number of patients able to achieve GRFS
MENLO PARK, Calif.--(BUSINESS WIRE)-- Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, today announced that new clinical data will be presented at the American Society of Hematology (ASH) Annual Meeting from December 10-13. Specifically, an oral presentation will include new data on relapse-free survival with Orca Bio’s lead investigational high-precision cell therapy, Orca-T. Additionally, results from Orca Bio’s Phase 1 clinical trial of its second investigational cell therapy, Orca-Q, in patients with haploidentical donors will be presented for the first time in an oral presentation.
Orca Bio will also share two poster presentations featuring data on immune reconstitution and elevated regulatory T cell frequencies in patients treated with Orca-T, as well as an analysis of the cost burden of allogeneic hematopoietic cell transplants and the potential value of addressing this unmet need.
ASH abstracts are now available at www.hematology.org. Details of the Orca Bio presentations follow:
Oral Presentations:
Title: Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Abstract Number: 265
Date and Time: Saturday, December 10, 2022, at 2 p.m. CST
Location: 391-392, Ernest N. Morial Convention Center
Presenter: Everett Meyer, M.D., Ph.D., Associate Professor of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford Health Care
Title: Orca-Q Demonstrates Favorable GvHD-and Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
Abstract Number: 769
Date and Time: Monday, December 12, 2022, at 10:30 a.m. CST
Location: 252-254, Ernest N. Morial Convention Center
Presenter: Amandeep Salhotra, M.D., Associate Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
Poster Presentations:
Title: Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
Abstract Number: 3408
Date and Time: Sunday, December 11, 2022, from 6 p.m. – 8 p.m. CST
Location: Hall D, Ernest N. Morial Convention Center
Title: Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need
Abstract Number: 4865
Date and Time: Monday, December 12, 2022, from 6 p.m. – 8 p.m. CST
Location: Hall D, Ernest N. Morial Convention Center
About Orca-T
Orca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being studied to treat multiple hematologic malignancies.
About Orca-Q
Orca-Q is an investigational allogeneic cellular therapy consisting of a single infusion containing a proprietary composition of stem and immune cells derived from peripheral blood from either related or unrelated matched, unmatched or haploidentical donors. Orca-Q is currently being studied to treat multiple hematologic malignancies in alternative donor settings, with and without GvHD prophylaxis.
About Orca Bio
Orca Bio is a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients’ blood and immune systems with healthy ones, but restore their quality of life. For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005163/en/
Contacts
Corporate Communications
media@orcabio.com
Investor Relations
Joshua Murray
ir@orcabio.com
Source: Orca Bio
View this news release online at:
http://www.businesswire.com/news/home/20221103005163/en
